These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38769210)

  • 1. Salivary, lacrimal and nasal (SALANS) measure to assess side effects following radioactive iodine treatment: development, psychometric properties, and factor structure.
    Jonklaas J; Carr AL; Luta G; Yu C; Jensen RE; Reasner E; Winslow J; Kuo CC; Davidson BJ; Esposito G; Bloom G; Diamond-Rossi SA; Graves KD
    Qual Life Res; 2024 Jul; 33(7):2011-2023. PubMed ID: 38769210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.
    Diamond-Rossi SA; Jonklaas J; Jensen RE; Kuo C; Stearns S; Esposito G; Davidson BJ; Luta G; Bloom G; Graves KD
    J Cancer Surviv; 2020 Dec; 14(6):847-857. PubMed ID: 32506220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
    Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of the information needs questionnaire for differentiated thyroid cancer patient with radioactive iodine therapy (INQ-DTC).
    Zhang J; Li L; Liu D; Zhu T; Gao Q; Chen H; Ma L; Li J; Wang Z
    Nurs Open; 2022 May; 9(3):1794-1804. PubMed ID: 34003590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction.
    Jonklaas J
    Thyroid; 2014 Dec; 24(12):1806-14. PubMed ID: 25090584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer.
    Dingle IF; Mishoe AE; Nguyen SA; Overton LJ; Gillespie MB
    Otolaryngol Head Neck Surg; 2013 May; 148(5):746-52. PubMed ID: 23462656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study.
    da Fonseca FL; Yamanaka PK; Mazoti L; Arakawa-Sugueno L; Kato JM; Matayoshi S
    Head Neck; 2017 Dec; 39(12):2381-2396. PubMed ID: 28945293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia.
    Bulut OC; Haufe S; Hohenberger R; Hein M; Kratochwil C; Rathke H; Plinkert PK; Baumann I; Holland-Letz T; Haberkorn U; Flechsig P
    Nuklearmedizin; 2018 Aug; 57(4):160-167. PubMed ID: 30125928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors of
    Hollingsworth B; Senter L; Zhang X; Brock GN; Jarjour W; Nagy R; Brock P; Coombes KR; Kloos RT; Ringel MD; Sipos J; Lattimer I; Carrau R; Jhiang SM
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4085-4093. PubMed ID: 27533304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
    Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
    Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
    [No Abstract]   [Full Text] [Related]  

  • 11. A Modular Health-Related Quality of Life Instrument for Electronic Assessment and Treatment Monitoring: Web-Based Development and Psychometric Validation of Core Thrive Items.
    Wicks P; McCaffrey S; Goodwin K; Black R; Hoole M; Heywood J
    J Med Internet Res; 2019 Jan; 21(1):e12075. PubMed ID: 30681962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DEVELOPMENT AND VALIDATION OF 'SURE': A PATIENT REPORTED OUTCOME MEASURE (PROM) FOR RECOVERY FROM DRUG AND ALCOHOL DEPENDENCE.
    Neale J; Vitoratou S; Finch E; Lennon P; Mitcheson L; Panebianco D; Rose D; Strang J; Wykes T; Marsden J
    Drug Alcohol Depend; 2016 Aug; 165():159-67. PubMed ID: 27344196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?
    Adramerinas M; Andreadis D; Vahtsevanos K; Poulopoulos A; Pazaitou-Panayiotou K
    Hormones (Athens); 2021 Dec; 20(4):669-678. PubMed ID: 34143403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation.
    Iakovou I; Goulis DG; Tsinaslanidou Z; Giannoula E; Katsikaki G; Konstantinidis I
    Head Neck; 2016 Apr; 38 Suppl 1():E227-30. PubMed ID: 25537365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Development and Validation of the Sexual and Relationship Distress Scale.
    Frost R; Donovan C
    J Sex Med; 2018 Aug; 15(8):1167-1179. PubMed ID: 30033190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactive Iodine in Differentiated Thyroid Carcinoma: A Systematic AGREE II Clinical Practice Guideline Appraisal.
    Monos S; Fritz C; Harris J; Romeo D; Ng JJ; Xu K; Cooperberg B; Moreira A; Rajasekaran K
    Otolaryngol Head Neck Surg; 2024 Jan; 170(1):20-33. PubMed ID: 37694597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
    Auttara-Atthakorn A; Sungmala J; Anothaisintawee T; Reutrakul S; Sriphrapradang C
    Front Endocrinol (Lausanne); 2022; 13():960265. PubMed ID: 36105397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients.
    Choi EK; Oh JK; Chung YA; Jeong H; Choi H; Jo K
    Int J Med Sci; 2024; 21(3):492-495. PubMed ID: 38250604
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.